Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study.

Heikkinen T, Young J, van Beek E, Franke H, Verstraeten T, Weil JG, Della Cioppa G.

Am J Obstet Gynecol. 2012 Sep;207(3):177.e1-8. doi: 10.1016/j.ajog.2012.07.007.

PMID:
22939717
2.

Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis.

Tsai T, Kyaw MH, Novicki D, Nacci P, Rai S, Clemens R.

Vaccine. 2010 Feb 17;28(7):1877-80. doi: 10.1016/j.vaccine.2009.11.077.

PMID:
19969117
3.

A/H1N1 pandemic influenza vaccination: A retrospective evaluation of adverse maternal, fetal and neonatal outcomes in a cohort of pregnant women in Italy.

Fabiani M, Bella A, Rota MC, Clagnan E, Gallo T, D'Amato M, Pezzotti P, Ferrara L, Demicheli V, Martinelli D, Prato R, Rizzo C.

Vaccine. 2015 May 5;33(19):2240-7. doi: 10.1016/j.vaccine.2015.03.041.

PMID:
25820060
4.

Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study.

Trotta F, Da Cas R, Spila Alegiani S, Gramegna M, Venegoni M, Zocchetti C, Traversa G.

BMJ. 2014 May 29;348:g3361. doi: 10.1136/bmj.g3361.

5.
6.

Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers.

Hwang SM, Kim HL, Min KW, Kim M, Lim JS, Choi JM, Chun BC, Kim MJ, Lee SM, Kim SY, Jeon HH.

Jpn J Infect Dis. 2012;65(3):193-7.

7.

Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study.

Rubinstein F, Micone P, Bonotti A, Wainer V, Schwarcz A, Augustovski F, Pichon Riviere A, Karolinski A; EVA Study Research Group Estudio Embarazo y Vacuna Antigripal..

BMJ. 2013 Feb 4;346:f393. doi: 10.1136/bmj.f393.

8.

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.

Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.

Vaccine. 2012 Jul 13;30(33):5030-7. doi: 10.1016/j.vaccine.2012.03.053.

PMID:
22472791
9.

Perinatal survival and health after maternal influenza A(H1N1)pdm09 vaccination: A cohort study of pregnancies stratified by trimester of vaccination.

Baum U, Leino T, Gissler M, Kilpi T, Jokinen J.

Vaccine. 2015 Sep 11;33(38):4850-7. doi: 10.1016/j.vaccine.2015.07.061.

PMID:
26238723
10.

Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.

Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, Mosca F, Principi N.

Pediatrics. 2011 May;127(5):e1161-8. doi: 10.1542/peds.2010-1920.

PMID:
21464195
11.

Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.

Zuccotti GV, Pariani E, Scaramuzza A, Santoro L, Giani E, Macedoni M, Gazzarri A, Anselmi G, Amendola A, Zanetti A.

Diabet Med. 2011 Dec;28(12):1530-6. doi: 10.1111/j.1464-5491.2011.03449.x.

PMID:
21916971
12.

A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic.

Reynales H, Astudillo P, de Vallière S, Hatz C, Schlagenhauf P, Rath B, Velentgas P, Fariña A, Sales-Carmona V, Groth N.

Vaccine. 2012 Oct 5;30(45):6436-43. doi: 10.1016/j.vaccine.2012.08.005.

PMID:
22902681
13.

A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two.

Moro ML, Nobilio L, Voci C, Di Mario S, Candela S, Magrini N; SaFoH1N1 working group..

Vaccine. 2013 Feb 27;31(10):1438-46. doi: 10.1016/j.vaccine.2012.07.090.

PMID:
22885015
14.

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.

Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, Pellegrini M, Sokal E, Vertruyen A.

Vaccine. 2010 Oct 21;28(45):7331-6. doi: 10.1016/j.vaccine.2010.08.075.

PMID:
20813217
15.

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G.

Vaccine. 2009 Nov 16;27(49):6959-65. doi: 10.1016/j.vaccine.2009.08.101.

PMID:
19751689
16.

Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects.

Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, Veitch K, Gaitatzis N.

Int J Clin Pract. 2010 Mar;64(4):432-8. doi: 10.1111/j.1742-1241.2009.02309.x.

PMID:
20039974
17.

In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells.

Bencharitiwong R, Leonard S, Tsai T, Nowak-Węgrzyn A.

Hum Vaccin Immunother. 2012 Jul;8(7):863-5. doi: 10.4161/hv.20324.

PMID:
22777093
18.

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.

Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A.

Pediatr Infect Dis J. 2009 Jul;28(7):563-71. doi: 10.1097/INF.0b013e31819d6394.

PMID:
19561422
19.

Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.

Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N.

Pediatr Infect Dis J. 2012 Apr;31(4):e59-65. doi: 10.1097/INF.0b013e31824b9545.

PMID:
22418661
20.

[Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].

Li RC, Fang HH, Li YP, Liu YP, Nong Y, Huang GB.

Zhonghua Liu Xing Bing Xue Za Zhi. 2008 Jun;29(6):548-51. Chinese.

PMID:
19040034
Items per page

Supplemental Content

Support Center